Assembly Biosciences (NASDAQ:ASMB) Rating Increased to Hold at BidaskClub

Assembly Biosciences (NASDAQ:ASMB) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday, BidAskClub reports.

A number of other analysts have also recently commented on ASMB. Zacks Investment Research cut shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Chardan Capital reiterated a “hold” rating and issued a $30.00 target price on shares of Assembly Biosciences in a research note on Monday, April 15th. Finally, William Blair reiterated an “outperform” rating on shares of Assembly Biosciences in a research note on Friday, May 10th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Assembly Biosciences currently has a consensus rating of “Buy” and an average price target of $43.00.

ASMB stock opened at $14.80 on Tuesday. The company has a market capitalization of $366.90 million, a P/E ratio of -3.72 and a beta of 1.60. The company has a quick ratio of 7.97, a current ratio of 7.97 and a debt-to-equity ratio of 0.06. Assembly Biosciences has a 52 week low of $13.13 and a 52 week high of $48.91.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.01. The company had revenue of $3.89 million during the quarter, compared to analysts’ expectations of $3.81 million. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. As a group, equities research analysts forecast that Assembly Biosciences will post -4.34 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ASMB. Bank of New York Mellon Corp raised its holdings in shares of Assembly Biosciences by 17.4% during the third quarter. Bank of New York Mellon Corp now owns 80,233 shares of the biopharmaceutical company’s stock valued at $2,979,000 after purchasing an additional 11,902 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Assembly Biosciences by 3.8% during the third quarter. JPMorgan Chase & Co. now owns 82,769 shares of the biopharmaceutical company’s stock valued at $3,074,000 after purchasing an additional 3,022 shares during the last quarter. Morgan Stanley raised its holdings in shares of Assembly Biosciences by 13.8% during the third quarter. Morgan Stanley now owns 76,824 shares of the biopharmaceutical company’s stock valued at $2,854,000 after purchasing an additional 9,310 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Assembly Biosciences by 52.9% during the fourth quarter. Rhumbline Advisers now owns 27,744 shares of the biopharmaceutical company’s stock valued at $628,000 after purchasing an additional 9,602 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Assembly Biosciences by 3.4% during the fourth quarter. Victory Capital Management Inc. now owns 530,909 shares of the biopharmaceutical company’s stock valued at $12,009,000 after purchasing an additional 17,669 shares during the last quarter. 86.44% of the stock is owned by institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Featured Story: How to execute a trade ex-dividend strategy?

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.